Net margin is calculated as Net Income divided by its Revenue. AB Science's Net Income for the
six
months ended in Dec. 2025 was €3.62 Mil. AB Science's Revenue for the
six
months ended in Dec. 2025 was €0.66 Mil. Therefore, AB Science's net margin for the quarter that ended in Dec. 2025 was 549.32%.
The historical rank and industry rank for AB Science's Net Margin % or its related term are showing as below:
XPAR:AB'
s Net Margin % Range Over the Past 10 Years
Min: -1836.6 Med: -1309.93 Max: -132.62
Current: -132.62
XPAR:AB's Net Margin % is ranked worse than 92.26% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs XPAR:AB: -132.62
AB Science (XPAR:AB) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
AB Science Net Margin % Related Terms
AB Science Net Margin % Historical Data
* Premium members only.
The historical data trend for AB Science's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:AB vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AB Science's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AB Science Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AB Science's Net Margin % distribution charts can be found below:
* The bar in red indicates where AB Science's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AB Science (XPAR:AB) has a Net Margin % of 549.32% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on AB Science and its competitors. According to the industry distribution chart, AB Science ranks #882 out of 956 companies in the Drug Manufacturers industry, placing it in the top 92.3%.
Is AB Science's Net Margin % too high?
AB Science's current Net Margin % is 549.32%. The Drug Manufacturers industry median Net Margin % is 5.56. AB Science's value of 549.32% is 9779.9% above this industry median. Based on the distribution chart, AB Science ranks #882 out of 956 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AB Science has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AB Science's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AB Science ranks #882 out of 956 companies for Net Margin %. This places AB Science in the lower half of its industry. The industry median Net Margin % is 5.56. AB Science's value of 549.32% is 9779.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AB Science's current Net Margin % of 549.32% is 9779.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on AB Science and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AB Science's current Net Margin % is 549.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AB Science stock overvalued right now?
Based on GuruFocus' analysis, AB Science (XPAR:AB) is currently considered Possible Value Trap. The stock's GF Value™ is €1.47, compared to a current price of €0.86 — trading 41.6% below its estimated fair value. The current Net Margin % is 549.32% and 9779.9% above the Drug Manufacturers industry median of 5.56. AB Science's overall GF Score™ is 59/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For AB Science (XPAR:AB), the current Net Margin % is 549.32% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AB Science (XPAR:AB) Overvalued in 2026?
Based on GuruFocus' analysis, AB Science stock appears to be undervalued.
The current stock price of €0.86 is trading 41.6% below its estimated GF Value™ of €1.47.
GuruFocus considers AB Science to be Possible Value Trap.
Key valuation signals for XPAR:AB:
Net Margin %: 549.32%
GF Value™: €1.47 vs. price of €0.86 (41.6% below fair value)
Industry Position: 9779.9% above the Drug Manufacturers median (#882 of 956)
No single metric tells the full story. See the XPAR:AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of medicines targeting unmet medical needs, based on two platforms. Masitinib platform: It is based on masitinib, a selective protein kinase inhibitor in development for neurodegenerative diseases, oncology, & inflammatory diseases. It has the clinical development of masitinib in neurodegenerative diseases (specifically Alzheimer's disease, amyotrophic lateral sclerosis, & progressive forms of multiple sclerosis). ALDH/Microtubule Platform: It is a portfolio of synthetic agents that target cancer cells by destabilising microtubules, which are essential for cell division & cancer stem cells, by inhibiting enzymes that are essential for maintaining their physiological state & survival.
59GF Score
Get the complete analysis for XPAR:AB
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:AB has been successfully added to your 
